Stocks and Investing
Stocks and Investing
Thu, May 2, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Michael Petusky Maintained (SRDX) at Buy and Held Target at $71 on, May 2nd, 2024
Michael Petusky of Barrington Research, Maintained "Surmodics, Inc." (SRDX) at Buy and Held Target at $71 on, May 2nd, 2024.
Michael has made no other calls on SRDX in the last 4 months.
There is 1 other peer that has a rating on SRDX. Out of the 1 peers that are also analyzing SRDX, 0 agree with Michael's Rating of Hold.
This is the rating of the analyst that currently disagrees with Michael
- Mike Matson of "Needham" Maintained at Strong Buy with Decreased Target to $43 on, Wednesday, May 1st, 2024
Contributing Sources